In a recent webcast, Dr. Ronald Korn, Founder and CMO at Imaging Endpoints and Kelie Williams Luby, VP Clinical Trials Software at Mint Medical, presented an integrated, comprehensive analysis using the mint Lesion™ platform for a seamless evaluation of COVID-19 patients and trials.
Together they highlighted the need for expert image analysis and the urgent need for organized data collection, encompassing the multi-dimensional data of imaging, laboratory, clinical, and demographics for COVID-19.
While imaging should not be used as a screening tool for unselected populations, it supports a comprehensive approach which can be applied in both clinical care and clinical trials. The mint Lesion™ platform integrates this multi-dimensional data creating a digital signature for the patient while enabling data quality, integrity, and traceability acquired in a high-trust environment.
-
65 minute(s)
Radiologic Analysis of COVID-19 Infection
Related Resources
Related Resources
Medical University of Innsbruck: Radiomic Assessment of Radiation-Induced Alterations of Skeletal Muscle Composition in Head and Neck Squamous Cell Carcinoma within the Currently Clinically Defined Optimal Time Window for Salvage Surgery
This study [1] aimed to examine tissue changes in patients with head and neck squamous cell carcinoma (HNSCC) after primary radiochemotherapy (RCT)…
The Mint Mission
Join our three Sales Directors, Felix Gruler, Aditya Jayaram, and Steffen Rupp, in their discussion about Mint Medical’s mission statements and how we…
University of Miami & Nova Souteastern University: Study shows feasibility of radiomics and T2 mapping as novel imaging biomarkers of activity in superficial fibromatosis
A retrospective study [1] conducted by researchers at University of Miami Miller School of Medicine and Nova Southeastern University investigated…